Hologic, Inc. (NASDAQ:HOLX) Shares Sold by Davis R M Inc.

Davis R M Inc. cut its holdings in Hologic, Inc. (NASDAQ:HOLX) by 9.3% in the 3rd quarter, HoldingsChannel reports. The fund owned 4,259 shares of the medical equipment provider’s stock after selling 439 shares during the period. Davis R M Inc.’s holdings in Hologic were worth $347,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the business. Swedbank AB purchased a new stake in shares of Hologic in the first quarter valued at $120,827,000. Black Creek Investment Management Inc. boosted its stake in Hologic by 60.9% in the 2nd quarter. Black Creek Investment Management Inc. now owns 2,338,970 shares of the medical equipment provider’s stock worth $173,669,000 after buying an additional 885,524 shares during the last quarter. Mackenzie Financial Corp grew its holdings in Hologic by 1,023.3% in the 2nd quarter. Mackenzie Financial Corp now owns 895,699 shares of the medical equipment provider’s stock valued at $66,506,000 after buying an additional 815,960 shares during the period. Marshall Wace LLP acquired a new position in shares of Hologic during the 2nd quarter valued at about $39,427,000. Finally, The Manufacturers Life Insurance Company lifted its holdings in shares of Hologic by 21.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,535,258 shares of the medical equipment provider’s stock worth $188,243,000 after acquiring an additional 450,190 shares during the period. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

Hologic stock opened at $79.73 on Tuesday. The firm has a market capitalization of $18.52 billion, a PE ratio of 23.94, a price-to-earnings-growth ratio of 2.49 and a beta of 0.98. Hologic, Inc. has a one year low of $67.59 and a one year high of $84.67. The stock’s 50 day moving average price is $80.38 and its 200 day moving average price is $78.38. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69.

Hologic (NASDAQ:HOLX) last posted its earnings results on Monday, November 4th. The medical equipment provider reported $1.01 EPS for the quarter, hitting analysts’ consensus estimates of $1.01. The business had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.89 earnings per share. As a group, sell-side analysts expect that Hologic, Inc. will post 4.27 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on HOLX. Evercore ISI boosted their target price on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a report on Tuesday, October 1st. StockNews.com raised shares of Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Leerink Partners cut their target price on Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. UBS Group boosted their price target on Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, JPMorgan Chase & Co. upped their price target on Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Hologic has an average rating of “Moderate Buy” and a consensus price target of $89.91.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.